National Class A Foreign Expert | Core Expert, Guizhou Provincial Medical & Health Expert Group for Aiding Guizhou | Migrant Scholar, Zunyi Medical University | Senior Member, American Association for Cancer Research (AACR)

Educational Background

• 1987: Earned his Bachelor of Science degree in Biochemistry from Lanzhou University.
• 1990: Completed his Master’s degree at the School of Medicine, Southeast University.
• 2000: Awarded his Doctorate in Molecular Medicine from the Karolinska Institute (Sweden)—the host institution of the Nobel Committee for Physiology or Medicine.

Professional Experience

1. 1990–1995: Held successive roles as Lecturer, Assistant Professor, and Associate Professor (promoted ahead of the regular tenure track) at the School of Medicine, Southeast University.
   • Established multiple key technical platforms for the department, covering molecular hybridization, PCR, DNA synthesis, and DNA sequence analysis.
   • Published over 30 academic papers within 5 years, secured 3 provincial- and ministerial-level scientific and technological achievement awards, and was named "Model Excellent Teacher." He was also selected as a "Ministry-level Key Talent for Priority Cultivation."
2. 2000–2010: Worked as a Postdoctoral Fellow and later Research Scientist at the Van Andel Institute (USA).
3. 2011: Served as a Senior Research Fellow at the National Cancer Centre Singapore and the Joint Graduate School of the National University of Singapore & Duke University (USA).
4. 2011–2016: Held the position of Research Associate Professor & Co-Director of the Renal Cancer Research Laboratory, Department of Urology, University of Rochester Medical Center (USA).

Expertise & Academic Accomplishments

• Professor Chen possesses extensive expertise in molecular biology, molecular medicine, mouse models, and medicinal chemistry. He has led research on a broad range of genetic diseases and cancers, with over 120 papers published in peer-reviewed journals including Nature Genetics, Cancer Cell, Cancer Research, and Kidney International.
• Key Scientific Contributions:
  • Employed Positional Cloning technology to independently clone or co-clone four kidney cancer-associated genes: NORE1, LSAMP, HRPT2, and FLCN.
  • Developed multiple kidney cancer gene-targeted mouse models via gene targeting technology, including Flcn-Sglt2-Cre, Flcn-Ksp-Cre, Flcn-ER-Cre, Flcn-CMV-Cre, Vhl-Sglt2-Cre, Hrpt2-CMV-Cre, Pbrm1-Ksp-Cre, Pbrm1-Sglt2-Cre, Pbrm1-CMV-Cre, Vhl-Flcn double-knockout, and Vhl-Pbrm1 double-knockout models.
    • Notably, the Flcn gene-targeted mouse model (strain: 028718 - B6.129S4(SJL)-Flcntm1Btt/JdchJ) was donated to The Jackson Laboratory (a world-renowned mouse research hub) and has been adopted by an international pharmaceutical company for disease-related drug development.
• Awards & Recognition:
  • Twice honored with AACR Awards at international cancer conferences: the AACR-Bristol-Myers Squibb Oncology Scholar Award (2003) and the AACR-Sanofi-Aventis Scholar Award (2009).
  • Invited to speak at a 2003 press conference hosted by AACR, with his achievements covered by numerous local media organizations.
• Monographs: Edited and published influential works including Introduction to Human Genetics (1996), Renal Tumor (2013), Colorectal Cancer (2018), Renal Cell Carcinoma (2023), and Advances in Diagnosis and Therapy of Colorectal Carcinoma (2024).

Role at the Current Company (Since 2016)

• Establishing and optimizing a high-throughput in vitro cell screening platform for anti-tumor metastasis, multiple in vitro cell validation platforms, over 10 in vivo animal models for cancer cell metastasis validation, and a medicinal chemistry R&D platform.
• Screening four drug libraries (encompassing over 20,000 small-molecule compounds) and optimizing hit compounds to develop multiple anti-cancer metastasis drugs, wound healing agents, and anti-COVID-19 drugs.
• Securing nearly 30 national patents for these innovations.